/CVRX
CVRX Stock - CVRx, Inc.
Healthcare|Medical - DevicesNASDAQ
$8.03+1.39%
+$0.11 (+1.39%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.33
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+61.9%upside
Target: $13.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CVRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.95 – $8.11
TARGET (TP)$13.00
STOP LOSS$7.39
RISK/REWARD1:7.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.25
52W High$18.55
52W Low$4.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $51.29M | $39.30M | $22.47M | $13.04M | $6.05M |
| Gross Profit | $42.96M | $33.04M | $17.47M | $9.40M | $4.61M |
| Gross Margin | 83.8% | 84.1% | 77.8% | 72.1% | 76.2% |
| Operating Income | $-59,490,000 | $-43,103,000 | $-42,527,000 | $-25,968,000 | $-11,514,000 |
| Net Income | $-59,965,000 | $-41,199,000 | $-41,428,000 | $-43,078,000 | $-14,109,000 |
| Net Margin | -116.9% | -104.8% | -184.4% | -330.5% | -233.1% |
| EPS | $-2.65 | $-1.99 | $-2.02 | $-2.11 | $-0.73 |
Company Overview
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$15
Average Target
↑ 85.0% Upside
Now
$7
Low
$15
Average
$23
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 9th 2025 | JP Morgan | Downgrade | Underweight | $7 |
| January 14th 2025 | William Blair | Upgrade | Outperform | - |
| September 10th 2024 | Cantor Fitzgerald | Initiation | Overweight | $14 |
| July 11th 2024 | Lake Street | Reiterated | Buy | $12← $18 |
| May 1st 2024 | Craig Hallum | Resumed | Buy | $23← $30 |
| May 1st 2024 | JP Morgan | Downgrade | Neutral | $13← $36 |
| May 1st 2024 | William Blair | Downgrade | Market Perform | - |
| January 31st 2023 | Lake Street | Initiation | Buy | $20 |
| July 18th 2022 | Craig Hallum | Initiation | Buy | $15 |
Earnings History & Surprises
CVRXBeat Rate
50%
Last 18 quarters
Avg Surprise
-8.7%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$-0.49
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.44vs$-0.55
Q2 24
-96.2%
$-1.04vs$-0.53
Q3 24
-27.5%
$-0.65vs$-0.51
Q4 24
-26.7%
$-0.57vs$-0.45
Q1 25
-16.2%
$-0.43vs$-0.37
Q2 25
+5.4%
$-0.53vs$-0.56
Q3 25
-9.6%
$-0.57vs$-0.52
Q4 25
+2.0%
$-0.49vs$-0.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $-0.42 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.50 | $-0.49 | +2.0% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-0.52 | $-0.57 | -9.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.56 | $-0.53 | +5.4% | ✓ BEAT |
Q1 2025 | Feb 4, 2025 | $-0.37 | $-0.43 | -16.2% | ✗ MISS |
Q4 2024 | Oct 29, 2024 | $-0.45 | $-0.57 | -26.7% | ✗ MISS |
Q3 2024 | Jul 29, 2024 | $-0.51 | $-0.65 | -27.5% | ✗ MISS |
Q2 2024 | Apr 30, 2024 | $-0.53 | $-1.04 | -96.2% | ✗ MISS |
Q1 2024 | Jan 25, 2024 | $-0.55 | $-0.44 | +20.0% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $-0.57 | $-0.43 | +24.6% | ✓ BEAT |
Q3 2023 | Jul 25, 2023 | $-0.57 | $-0.56 | +1.8% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q1 2023 | Jan 26, 2023 | $-0.55 | $-0.51 | +7.3% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $-0.56 | $-0.48 | +14.3% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $-0.54 | $-0.54 | 0.0% | = MET |
Q2 2022 | Apr 25, 2022 | $-0.49 | $-0.49 | 0.0% | = MET |
Q1 2022 | Feb 15, 2022 | $-0.43 | $-0.52 | -20.9% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.38 | $-0.30 | +21.1% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-30.49 | $-48.48 | -59.0% | ✗ MISS |
Latest News
Canaccord Genuity Maintains Buy on CVRx, Raises Price Target to $11
📈 PositiveBenzinga•Nov 6, 2025, 07:58 PM•Also:
Cantor Fitzgerald Maintains Overweight on CVRx, Raises Price Target to $13
📈 PositiveBenzinga•Nov 6, 2025, 02:30 PM
CVRx Sees Q4 Sales $15.000M-$16.000M vs $15.846M Est
➖ NeutralBenzinga•Nov 5, 2025, 09:31 PM
CVRx Narrows FY2025 Sales Guidance from $55.000M-$57.000M to $55.600M-$56.600M vs $55.980M Est
➖ NeutralBenzinga•Nov 5, 2025, 09:31 PM
CVRx Q3 EPS $(0.49) Beats $(0.50) Estimate, Sales $14.690M Beat $14.157M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:30 PM
CVRx downgraded at J.P. Morgan after Q1 sales miss
📉 NegativeSeeking Alpha•May 9, 2025, 06:51 PM
Frequently Asked Questions about CVRX
What is CVRX's current stock price?
CVRx, Inc. (CVRX) is currently trading at $8.03 per share. The stock has moved +1.39% today.
What is the analyst price target for CVRX?
The average analyst price target for CVRX is $13.00, based on 1 analyst.
What sector is CVRx, Inc. in?
CVRx, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is CVRX's market cap?
CVRx, Inc. has a market capitalization of $0.21 billion, making it a small-cap company.
Does CVRX pay dividends?
No, CVRx, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCERS
Cerus Corporation
$2.09
Mkt Cap: $0.4B
MASS
908 Devices Inc.
$5.84
Mkt Cap: $0.2B
NNOX
Nano-X Imaging Ltd.
$2.99
Mkt Cap: $0.2B
OMI
Owens & Minor, Inc.
$2.84
Mkt Cap: $0.2B
PRQR
ProQR Therapeutics N.V.
$2.21
Mkt Cap: $0.2B
QTRX
Quanterix Corporation
$6.59
Mkt Cap: $0.3B
SENS
Senseonics Holdings, Inc.
$6.15
Mkt Cap: $0.3B
SGHT
Sight Sciences, Inc.
$8.45
Mkt Cap: $0.4B
SNWV
SANUWAVE Health, Inc.
$32.25
Mkt Cap: $0.3B
VMD
Viemed Healthcare, Inc.
$7.42
Mkt Cap: $0.3B
Explore stocks similar to CVRX for comparison